Gemina Laboratories Ltd.
GLABF · OTC
10/31/2025 | 7/31/2025 | 4/30/2025 | 1/31/2025 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 1.35 | 0.54 | 0.53 | -0.13 |
| FCF Yield | 0.09% | -0.05% | 0.04% | -0.08% |
| EV / EBITDA | -112.19 | -136.95 | -108.13 | -35.69 |
| Quality | ||||
| ROIC | 9.58% | 9.11% | 16.69% | 44.16% |
| Gross Margin | 0.00% | 0.00% | 100.00% | 0.00% |
| Cash Conversion Ratio | -0.10 | 0.07 | -0.04 | 0.03 |
| Growth | ||||
| Revenue 3-Year CAGR | 221,472.75% | 221,472.75% | 221,472.75% | -100.00% |
| Free Cash Flow Growth | 216.31% | -168.03% | 187.12% | 79.66% |
| Safety | ||||
| Net Debt / EBITDA | -0.73 | -0.59 | -0.33 | -0.94 |
| Interest Coverage | 0.00 | 0.00 | -17.41 | -32.96 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -115,527.63 | -96,660.00 | 311.09 | 0.00 |